CA2944959C - Derives heterocycliques contenant de l'azote substitue, compositions pharmaceutiques en comprenant et leurs utilisations dans le cadre de la lutte antitumorale - Google Patents

Derives heterocycliques contenant de l'azote substitue, compositions pharmaceutiques en comprenant et leurs utilisations dans le cadre de la lutte antitumorale Download PDF

Info

Publication number
CA2944959C
CA2944959C CA2944959A CA2944959A CA2944959C CA 2944959 C CA2944959 C CA 2944959C CA 2944959 A CA2944959 A CA 2944959A CA 2944959 A CA2944959 A CA 2944959A CA 2944959 C CA2944959 C CA 2944959C
Authority
CA
Canada
Prior art keywords
methyl
pyrazol
chloro
compound
formamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2944959A
Other languages
English (en)
Other versions
CA2944959A1 (fr
Inventor
Xiaowu DONG
Bo Yang
Jia Li
Wenhu ZHAN
Qinjie WENG
Yubo ZHOU
Yongzhou Hu
Lei Xu
Tao Liu
Qiaojun HE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University ZJU
Shanghai Institute of Materia Medica of CAS
Original Assignee
Zhejiang University ZJU
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University ZJU, Shanghai Institute of Materia Medica of CAS filed Critical Zhejiang University ZJU
Publication of CA2944959A1 publication Critical patent/CA2944959A1/fr
Application granted granted Critical
Publication of CA2944959C publication Critical patent/CA2944959C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux dérivés hétérocycliques contenant de l'azote substitué, représentés par la formule (I) et utilisables en tant qu'inhibiteurs de la kinase AKT, leurs isomères optiques, leurs sels pharmaceutiquement acceptables ou leurs solvates, formule (I) dans laquelle R1, R2, R3, R4, R5, R6, le cycle A, le cycle C, B, Q, Y, Z et m sont tels que définis de façon détaillée dans la description. De plus, l'invention concerne des médicaments contenant ces dérivés en tant que composants actifs, lesquels médicaments peuvent être utilisés pour le traitement de maladies prolifératives, telles que le cancer et l'inflammation et, en particulier, pour des maladies associées à la kinase AKT.
CA2944959A 2014-03-22 2015-03-21 Derives heterocycliques contenant de l'azote substitue, compositions pharmaceutiques en comprenant et leurs utilisations dans le cadre de la lutte antitumorale Expired - Fee Related CA2944959C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201410108818 2014-03-22
CN201410108818.5 2014-03-22
CN201410124591.3A CN104926801B (zh) 2014-03-22 2014-03-30 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用
CN201410124591.3 2014-03-30
CN201510101220.8A CN104926788B (zh) 2014-03-22 2015-03-08 取代哌啶类衍生物、含其的药物组合物及其在抗肿瘤中的应用
CN201510101220.8 2015-03-08
PCT/CN2015/074813 WO2015144021A1 (fr) 2014-03-22 2015-03-21 Dérivés hétérocycliques contenant de l'azote substitué, compositions pharmaceutiques en comprenant et leurs utilisations dans le cadre de la lutte antitumorale

Publications (2)

Publication Number Publication Date
CA2944959A1 CA2944959A1 (fr) 2015-10-01
CA2944959C true CA2944959C (fr) 2020-06-09

Family

ID=54114242

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2944959A Expired - Fee Related CA2944959C (fr) 2014-03-22 2015-03-21 Derives heterocycliques contenant de l'azote substitue, compositions pharmaceutiques en comprenant et leurs utilisations dans le cadre de la lutte antitumorale

Country Status (6)

Country Link
US (1) US10233180B2 (fr)
EP (1) EP3124486B1 (fr)
JP (1) JP6559699B2 (fr)
CN (2) CN104926801B (fr)
CA (1) CA2944959C (fr)
WO (1) WO2015144021A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3423437A4 (fr) 2016-03-01 2019-07-24 Propellon Therapeutics Inc. Inhibiteurs de la liaison entre la protéine wdr5 et ses partenaires de liaison
WO2017147700A1 (fr) * 2016-03-01 2017-09-08 Ontario Institute For Cancer Research (Oicr) Inhibiteurs de la liaison protéine wdr5-protéine
WO2017156350A1 (fr) 2016-03-09 2017-09-14 K-Gen, Inc. Méthodes de traitement du cancer
CN108341801B (zh) * 2017-01-24 2020-05-12 浙江大学 多氟取代芳联杂环类衍生物、含其的药物组合物及其应用
CN107089968B (zh) * 2017-04-12 2019-06-18 南方医科大学 1-(2-氨基吡啶-4-基)-3-哌啶甲酰胺衍生物及其合成方法和应用
PT3762368T (pt) 2018-03-08 2022-05-06 Incyte Corp Compostos de aminopirazina diol como inibidores de pi3k-y
WO2020010003A1 (fr) 2018-07-02 2020-01-09 Incyte Corporation DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ
CN108752318B (zh) * 2018-07-11 2020-05-12 浙江大学 一种多氟取代芳联杂环类化合物的晶型、制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
WO2005066163A2 (fr) * 2004-01-05 2005-07-21 Astrazeneca Ab Heterocycles substitues et leurs utilisations
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
SG172385A1 (en) 2008-12-23 2011-08-29 Hoffmann La Roche Dihydropyridone amides as p2x7 modulators
WO2010093885A1 (fr) * 2009-02-12 2010-08-19 Glaxosmithkline Llc Inhibiteurs de l'activité d'akt
TW201103904A (en) * 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
CN102471284A (zh) 2009-07-30 2012-05-23 弗·哈夫曼-拉罗切有限公司 作为p2x7调节剂的二氢嘧啶酮酰胺
CN101921268B (zh) * 2010-08-27 2016-08-03 中山大学肿瘤防治中心 5-噻唑酰胺类化合物及生物学应用
MX2014013632A (es) * 2012-05-22 2015-02-05 Univ North Carolina Compuestos de pirimidina para el tratamiento de cancer.
EP2895474B1 (fr) * 2012-09-17 2019-12-11 Duke University Modulateurs du récepteur smoothened et leurs procédés d'utilisation

Also Published As

Publication number Publication date
JP6559699B2 (ja) 2019-08-14
WO2015144021A1 (fr) 2015-10-01
EP3124486B1 (fr) 2020-12-09
CA2944959A1 (fr) 2015-10-01
CN104926801B (zh) 2019-06-04
JP2017512796A (ja) 2017-05-25
US10233180B2 (en) 2019-03-19
CN104926801A (zh) 2015-09-23
US20170107213A1 (en) 2017-04-20
CN104926788B (zh) 2018-08-28
EP3124486A1 (fr) 2017-02-01
CN104926788A (zh) 2015-09-23
EP3124486A4 (fr) 2017-08-23

Similar Documents

Publication Publication Date Title
CA2944959C (fr) Derives heterocycliques contenant de l'azote substitue, compositions pharmaceutiques en comprenant et leurs utilisations dans le cadre de la lutte antitumorale
JP6517928B2 (ja) キナーゼ阻害剤として有用なインドールカルボキシアミド
JP5977779B2 (ja) ２−（２，４，５−置換−アニリノ）ピリミジン化合物
AU2016280717C1 (en) Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
CN102985417B (zh) 作为jak1抑制剂的哌啶-4-基氮杂环丁烷衍生物
CN109422755A (zh) 一种含氮杂环化合物、制备方法、中间体、组合物和应用
JP6457623B2 (ja) ２，４−二置換７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法および医薬における使用
CN114269735A (zh) 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
WO2015127872A1 (fr) Dérivés de 1,5-diamine phénylène 2,4-disubstitués et leurs applications, compositions pharmaceutiques et compositions pharmaceutiquement acceptables préparées à partir de ces dérivés
CA3134261A1 (fr) Derives de 6-(isooxazolidine-2-yl)-n-phenylpyrimidine-4-amine comme inhibiteurs du facteur de croissance epidermique
CN105814053B (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
TWI669300B (zh) 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途
WO2007114323A1 (fr) Composé d'aminopyrrolidine
WO2019141202A9 (fr) Inhibiteur de kinase de la famille tam/et csf1r et son utilisation
KR20200011977A (ko) 아미노피리미딘 화합물, 이의 제조방법 및 용도
CA3174845A1 (fr) Pyridines substituees pour le traitement de maladies inflammatoires
CN114907341A (zh) 吡啶并嘧啶酮类衍生物及其制备方法和用途
RU2444515C2 (ru) Производное амида индазолакриловой кислоты
CN112313207B (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
EP4267137A1 (fr) Dérivés de pyrimidine à fusion hétéroaryle lactame servant d'inhibiteurs d'erbb2
WO2016098793A1 (fr) Dérivé thiazole ayant un groupe guanidyle cyclique
TW201708208A (zh) 新醫藥化合物
AU2013204962B2 (en) Polymorphic form of a mesylate salt of n-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
WO2017126635A1 (fr) Composé hétérocyclique et utilisation de celui-ci

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180307

MKLA Lapsed

Effective date: 20220321